| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4cdf984e52e386742b6ba53f2672f7d3 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S530-826
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-24222
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-24234 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-29
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-29
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-711
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-18 |
| filingDate |
1997-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5736b36ed6d91ff6648e281553ec4820 |
| publicationDate |
1998-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
FR-2760367-A1 |
| titleOfInvention |
VACCINE COMPOSITION FOR THE PREVENTION OR TREATMENT OF HEPATITIS C |
| abstract |
The subject of the present invention is a pharmaceutical composition intended for the treatment or prevention of infections induced by the hepatitis C virus (HCV), which according to a preferred mode, comprises, as active principle, (i) a polypeptide of a fusion comprising the capsid polypeptide (C191) and the envelope polypeptide (E1) of HCV and in which at least one of the clivagel73 / 174 and 191/192 sites has been rendered inoperative by mutation; (ii) an equimolar mixture of the C191 polypeptide whose cleavage site 173/174 has been rendered inoperative and of the E1 polypeptide (mixture equivalent to the fusion polypeptide) or (ii) a DNA molecule coding for this fusion polypeptide. The interest of products (i) to (iii) lies in that the element Cl91 is incapable of regulating the functioning of genes, in particular of transactivating them. A composition according to the invention can also comprise any form equivalent to the products described above. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6284249-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6538123-B2 |
| priorityDate |
1997-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |